A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Why is the quadra Study Being Done?

Treatment options become limited once women have had multiple regimens of chemotherapy. This study will look at how safe and effective niraparib is when given after women have had three or four previous regimens of chemotherapy.

NOTE: Enrollment goal has been reached.
This study is no longer enrolling new participants.

  • High-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease.
  • Have completed 3 or 4 previous chemotherapy regimens.
  • Have finished the last chemotherapy regimen more than 4 weeks before the study treatment begins.
  • Participants will have HRD testing (tumor) and gBRCA testing (blood)
  • Must not have had pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.
  • Must not have had a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.
  • Must not have (or had) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

How do I Know if the Quadra Trial is Right for Me?

The best next step is to contact the research site that would be the most convenient for you in order to discuss your medical history and whether the QUADRA clinical trial would be a good fit.

To find sites in your area, contact: clinicaltrials@tesarobio.com or use the form above.

To find additional information on QUADRA see: Clinicaltrials.gov